Schedule 13G ownership disclosure

CRISPR Therapeutics AG

Common Stock · CUSIP: H17182108

Event date: 2026-01-30

Filing-level shares
1,186,794.00
Percent of class
1.2%
  • Capital International Investors

    Shares: 1,186,794.00 · Class: 1.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001562230-26-000001
Form type
SCHEDULE 13G/A
Filer
CRISPR Therapeutics AG
CIK
CIK 1674416
Filed
Feb 05, 2026
Reporting period
Jan 30, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub